His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome. Previously, he developed a second generation vaccine against hepatitis B virus and an experimental vaccine against HIV/AIDS by using state-of-the-art technologies of genetic engineering and biotechnology. Recently, his Phase I human clinical trial of SAV001 prophylactic HIV vaccine, based on genetically modified killed-whole HIV-1, was successfully completed and preparing for the Phase II trial. Dr. Kang has published 135 peer reviewed research papers and 149 scientific proceedings and abstracts in the fields of virology, Immunology, molecular biology, and medicine. He holds nine international biotechnology patents that cover over 70 countries.
Universal viral vectors for prophylactic vaccines against infectious diseases and for therapeutic vaccines against persistent viral infections.